Tumour necrosis factor receptor-1 associated periodic syndrome (TRAPS)-related AA amyloidosis : a national case series and systematic review
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissionsoup.com..
OBJECTIVES: TNF receptor-1-associated periodic syndrome (TRAPS) is a rare autosomal dominant autoinflammatory disorder associated with mutations in the TNF receptor super family 1 A (TNFRSF1A) gene. AA amyloidosis (AA) is the most severe complication of TRAPS. To study the occurrence and prognosis of AA in TRAPS, we conducted a retrospective study of all French cases and a systematic literature review.
METHODS: This case series includes TRAPS patients followed by our centre from 2000 to 2020 presenting with histologically confirmed AA. We conducted a systematic literature review on the PubMed and EMBASE databases for articles published up to February 2021 following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines and using the keywords: amyloidoisis, amyloid, TNF receptor-associated periodic syndrome, TNF receptor-associated periodic syndrome, tumor necrosis factor receptor-associated periodic syndrome, TRAPS, TNFRSF1A, familial hibernian fever and hibernian familial fever.
RESULTS: A total of 41 TRAPS with AA were studied: three new patients and 38 cases from the literature. AA diagnosis preceded that of TRAPS in 96% of cases, and 17/36 (47%) required renal replacement therapy. Death occurred in 5/36 (14%) with a median follow-up of 23 months. Effect of biologics on AA were available for 21 regimens in 19 patients: 10 improved renal function, seven stabilized and four worsened. Four patients (36% of transplanted patients) relapse AA on kidney graft (only one under etanercept).
CONCLUSION: TRAPS is revealed by AA in most cases. Therefore, clinical features of TRAPS should be screened for in AA patients. IL-1 antagonist can help to normalize inflammation and to preserve renal function.
| Errataetall: |
CommentIn: Rheumatology (Oxford). 2021 Dec 1;60(12):5493-5494. - PMID 34559209 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
Rheumatology (Oxford, England) - 60(2021), 12 vom: 01. Dez., Seite 5775-5784 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Delaleu, Jérémie [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.12.2021 Date Revised 29.12.2021 published: Print CommentIn: Rheumatology (Oxford). 2021 Dec 1;60(12):5493-5494. - PMID 34559209 Citation Status MEDLINE |
|---|
| doi: |
10.1093/rheumatology/keab252 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322718082 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322718082 | ||
| 003 | DE-627 | ||
| 005 | 20231225182632.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/rheumatology/keab252 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1075.xml |
| 035 | |a (DE-627)NLM322718082 | ||
| 035 | |a (NLM)33715002 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Delaleu, Jérémie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tumour necrosis factor receptor-1 associated periodic syndrome (TRAPS)-related AA amyloidosis |b a national case series and systematic review |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.12.2021 | ||
| 500 | |a Date Revised 29.12.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Rheumatology (Oxford). 2021 Dec 1;60(12):5493-5494. - PMID 34559209 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a OBJECTIVES: TNF receptor-1-associated periodic syndrome (TRAPS) is a rare autosomal dominant autoinflammatory disorder associated with mutations in the TNF receptor super family 1 A (TNFRSF1A) gene. AA amyloidosis (AA) is the most severe complication of TRAPS. To study the occurrence and prognosis of AA in TRAPS, we conducted a retrospective study of all French cases and a systematic literature review | ||
| 520 | |a METHODS: This case series includes TRAPS patients followed by our centre from 2000 to 2020 presenting with histologically confirmed AA. We conducted a systematic literature review on the PubMed and EMBASE databases for articles published up to February 2021 following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines and using the keywords: amyloidoisis, amyloid, TNF receptor-associated periodic syndrome, TNF receptor-associated periodic syndrome, tumor necrosis factor receptor-associated periodic syndrome, TRAPS, TNFRSF1A, familial hibernian fever and hibernian familial fever | ||
| 520 | |a RESULTS: A total of 41 TRAPS with AA were studied: three new patients and 38 cases from the literature. AA diagnosis preceded that of TRAPS in 96% of cases, and 17/36 (47%) required renal replacement therapy. Death occurred in 5/36 (14%) with a median follow-up of 23 months. Effect of biologics on AA were available for 21 regimens in 19 patients: 10 improved renal function, seven stabilized and four worsened. Four patients (36% of transplanted patients) relapse AA on kidney graft (only one under etanercept) | ||
| 520 | |a CONCLUSION: TRAPS is revealed by AA in most cases. Therefore, clinical features of TRAPS should be screened for in AA patients. IL-1 antagonist can help to normalize inflammation and to preserve renal function | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a AA amyloidosis | |
| 650 | 4 | |a TNFRSF1A | |
| 650 | 4 | |a Tumour necrosis factor receptor-1 associated periodic syndrome (TRAPS) | |
| 650 | 4 | |a interleukin 1 receptor antagonist protein | |
| 650 | 7 | |a Receptors, Tumor Necrosis Factor, Type I |2 NLM | |
| 650 | 7 | |a Serum Amyloid A Protein |2 NLM | |
| 650 | 7 | |a TNFRSF1A protein, human |2 NLM | |
| 650 | 7 | |a DNA |2 NLM | |
| 650 | 7 | |a 9007-49-2 |2 NLM | |
| 700 | 1 | |a Deshayes, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Rodrigues, Francois |e verfasserin |4 aut | |
| 700 | 1 | |a Savey, Lea |e verfasserin |4 aut | |
| 700 | 1 | |a Rivière, Etienne |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, Nicolas Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Aouba, Achille |e verfasserin |4 aut | |
| 700 | 1 | |a Amselem, Serge |e verfasserin |4 aut | |
| 700 | 1 | |a Rabant, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Grateau, Gilles |e verfasserin |4 aut | |
| 700 | 1 | |a Giurgea, Irina |e verfasserin |4 aut | |
| 700 | 1 | |a Georgin-Lavialle, Sophie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology (Oxford, England) |d 1999 |g 60(2021), 12 vom: 01. Dez., Seite 5775-5784 |w (DE-627)NLM102581908 |x 1462-0332 |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2021 |g number:12 |g day:01 |g month:12 |g pages:5775-5784 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/rheumatology/keab252 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 2021 |e 12 |b 01 |c 12 |h 5775-5784 | ||